Sava Infond d.o.o. Buys 700 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Sava Infond d.o.o. increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 46.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,200 shares of the company’s stock after buying an additional 700 shares during the quarter. Sava Infond d.o.o.’s holdings in TransMedics Group were worth $148,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. NBC Securities Inc. bought a new position in shares of TransMedics Group during the 1st quarter worth approximately $25,000. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $31,000. AlphaQuest LLC bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $52,000. Rakuten Securities Inc. lifted its position in shares of TransMedics Group by 68.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company’s stock worth $84,000 after buying an additional 550 shares during the period. Finally, Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company’s stock worth $86,000 after buying an additional 504 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 3.2%

NASDAQ TMDX opened at $127.53 on Tuesday. The stock has a fifty day moving average of $115.04 and a 200-day moving average of $84.67. The stock has a market capitalization of $4.31 billion, a P/E ratio of 93.77 and a beta of 2.10. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The business’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same period last year, the firm earned $0.35 EPS. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider now directly owns 13,955 shares of the company’s stock, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the sale, the director now directly owns 2,866 shares of the company’s stock, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,418 shares of company stock valued at $1,512,613 over the last three months. Company insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Oppenheimer raised their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 17th. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $127.33.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.